Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AmyPore logo — New target, new paradigm, new strategy that address the root...

AmyPore

New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies

Founded 2018 France France 2 employees Non Equity Assistance Total: $71.43K Biotechnology, Health Care +1

General Information

Company Name AmyPore
Founded Year 2018
Location France France +1
Employees 2
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Non Equity Assistance
Social

Get notified when AmyPore moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AmyPore

AmyPore is a biotechnology company with a focus on tackling neurodegenerative diseases such as Alzheimer and Parkinson. Founded in 2018 and based in France, the company is built around the groundbreaking work of Pr. Nouara Yahi and Pr. Jacques Fantini from the University of Aix-Marseille and Institut Universitaire de France. Their expertise in molecular neurosciences has led to the development of AmyP53, a patented non-toxic molecule designed to address a common mechanism of neurotoxicity in these debilitating diseases. The company's approach involves the use of a pioneering computational discovery platform and advanced binding technologies to identify and neutralize novel targets associated with pathologic protein misfolding. AmyPore also holds exclusive patent rights for the therapeutic use of AmyP53, including the development of a nasal spray for the treatment of Alzheimer's and Parkinson's diseases. Additionally, the company is working on a pipeline of therapeutic peptides aimed at preventing the formation of oligomers implicated in the development and progression of degenerative proteinopathies, such as amyotrophic lateral sclerosis (ALS) and type 2 diabetes. In April 2019, AmyPore secured Non-Equity Assistance investment from Incubateur Impulse, further validating the potential of their innovative approach. With its pioneering science and promising therapeutic developments, AmyPore has the potential to significantly impact the field of neurodegenerative disease treatment.

Taxonomy: neurosciences, drug development, therapeutic peptides, molecular dynamics simulations, neurodegenerative diseases, proteinopathies, Alzheimer's disease, Parkinson's disease, drug design, calcium imaging, lipid-protein interactions, neurotoxicity, oligomers

Services & Products

Development of therapeutic peptides for treating neurodegenerative diseases such as Alzheimer's and Parkinson's

Target Customers

Patients suffering from neurodegenerative diseases healthcare providers biotechnology and pharmaceutical companies research institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance •••••• 1
Investor
03 Apr 2019
Grant •••••• 1 •••• •••• 01 Jan 2019

AmyPore Alternatives & Competitors

AmyPore vs
ProMIS™ Neurosciences, Inc.
ProMIS™ Neurosciences, Inc. United States

Precision therapeutics for protein misfolding disorders, including Alzheimer's, ALS and Parkinson’s...

Unknown
22 employees
Biotechnology, Health Care
AmyPore vs
iniuva
iniuva Germany

we. fight. misfolding.

5 employees
Biotechnology, Health Care
AmyPore vs
Kineta (Reverse Merger With Yumanity Therapeutics)
Kineta (Reverse Merger With Yumanity Therapeutics)

Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfolding.

Series Unknown
Biotechnology, Health Care

FAQ About AmyPore

New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies
AmyPore was founded in 2018.
AmyPore is headquartered in France.
AmyPore operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
AmyPore has approximately 2 employees.
AmyPore has completed 2 funding rounds, raising a total of $71.43K. The latest funding stage is Non Equity Assistance.
AmyPore offers: Development of therapeutic peptides for treating neurodegenerative diseases such as Alzheimer's and Parkinson's.
Top alternatives and competitors to AmyPore include ProMIS™ Neurosciences, Inc., iniuva, Kineta (Reverse Merger With Yumanity Therapeutics), AnHorn Medicines, Gain Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AmyPore and ProMIS™ Neurosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AmyPore and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy